Moving beyond local practice: Reconfiguring the adoption of a breast cancer diagnostic technology by Maniatopoulos, Gregory et al.
Northumbria Research Link
Citation: Maniatopoulos, Gregory, Procter, Rob, Llewellyn, Sue, Harvey, Gill and Boyd, Alan (2015) 
Moving beyond local practice: Reconfiguring the adoption of a breast cancer diagnostic technology.  
Social Science & Medicine, 131. pp. 98-106. ISSN 0277-9536 
Published by: Elsevier
URL:  https://doi.org/10.1016/j.socscimed.2015.02.036 
<https://doi.org/10.1016/j.socscimed.2015.02.036>
This  version  was  downloaded  from  Northumbria  Research  Link: 
http://nrl.northumbria.ac.uk/id/eprint/44418/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to access 
the University’s research output. Copyright © and moral rights for items on NRL are retained by the 
individual author(s) and/or other copyright owners.  Single copies of full items can be reproduced, 
displayed or performed, and given to third parties in any format or medium for personal research or 
study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, 
title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata 
page. The content must not be changed in any way. Full items must not be sold commercially in any  
format or medium without formal permission of the copyright holder.  The full policy is available online: 
http://nrl.northumbria.ac.uk/pol  i cies.html  
This  document  may differ  from the  final,  published version of  the research  and has been made 
available online in accordance with publisher policies. To read and/or cite from the published version 
of the research, please visit the publisher’s website (a subscription may be required.)
                        

M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Moving Beyond Local Practice: Reconfiguring the Adoption of a Breast Cancer 
Diagnostic Technology 
 
 
 
Gregory Maniatopoulos 
Institute of Health and Society 
Newcastle University, UK 
gregory.maniatopoulos@ncl.ac.uk 
 
Rob Procter 
Department of Computer Science 
University of Warwick, UK 
rob.procter@warwick.ac.uk 
 
Sue Llewellyn 
Herbert Simon Institute 
University of Manchester, UK 
sue.llewellyn@mbs.ac.uk 
 
Gill Harvey 
Herbert Simon Institute 
University of Manchester, UK 
gill.harvey@mbs.ac.uk 
 
Alan Boyd 
Herbert Simon Institute 
University of Manchester, UK 
Alan.boyd@mbs.ac.uk 
 
 
*Corresponding author: Gregory Maniatopoulos, Institute of Health and Society, Baddiley-
Clark Building, Richardson Road, Newcastle University, NE2 4AX, UK, 
gregory.maniatopoulos@ncl.ac.uk 
 
Acknowledgements 
This article draws upon a three year research study funded by the National Institute of Health 
Research (HS&DR, 08/1820/254).This support is gratefully acknowledged. Ethical approval was 
gained from University of Manchester Research Ethics Committee, North West 12 Research Ethics 
Committee (09/H1015/80, 1
st
December 2010), Portsmouth Hospitals NHS Trust Research Ethics 
Committee (PHT/2009/74, 26
th
 April 2010), Princess Alexandra Hospital Trust Research Ethics 
Committee (559-240810, 20
th
 December 2010), University Hospital of North Staffordshire Research 
Ethics Committee  (5064/DC/kr, 10th  February 2011), South Devon Healthcare NHS Foundation 
Trust Research Ethics Committee (10/08/022, 14th October 2010) and subsequent amendments. We 
would like to thank Stefan Timmermans and the anonymous reviewers for their constructive 
comments which further improved this paper. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
Abstract 
This paper explores the ways in which technological innovation becomes adopted and 
incorporated into healthcare practice. Drawing upon the notion of ‘field of practices’, we 
examine how adoption is subject to spatially and temporally distributed reconfigurations 
across a multi-level set of practices, ranging from the policy level to the micro–level setting 
of individual action. The empirical backdrop is provided by a case study of the adoption of 
Breast Lymph Node Assay (BLNA), a diagnostic technology innovation for the treatment of 
breast cancer patients. Our aim is to contribute to the development of a more comprehensive 
analysis of the processes surrounding the adoption and incorporation of complex healthcare 
technologies into routine practice. 
Keywords: United Kingdom, technological innovation, reconfiguration, adoption, healthcare 
practice, diagnostic technology, breast cancer 
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Introduction 
In recent years, numerous studies have examined the characteristics of innovation in 
healthcare and its organizational context (Berwick, 2003; Ferlie et al., 2005; Fitzgerald et al., 
2002; Greenhalgh et al, 2004; 2005; Robert et al., 2010; Salaman and Storey, 2002). Such 
studies have identified several factors influencing the adoption of innovations. One important 
theme to emerge in both organisational and healthcare related literatures has been a 
consideration of how innovations become embedded into everyday practice (Colyvas and 
Johnson, 2011; May, 2013; May and Finch, 2009; May, 2006; Webster, 2002). Such concerns 
have led to the development of new theoretical ideas, which seek to better understand the 
adoption and embedding of new technologies (May, 2013). This paper contributes to this 
important theme in the context of technology adoption in healthcare practice.  
In particular, we argue that adoption of technological innovations should be understood as an 
emergent and contingent process in that it is constantly defined, redefined and negotiated 
across multiple contexts in space and time. Adoption encompasses a broad range of 
phenomena, including material objects, intra- and inter-organisational relations, knowledge 
practices, learning, power, politics, leadership, conflict resolution and competency 
development, and a successful outcome may depend upon complex reconfigurations of both 
technologies and practices, where technologies and their contexts of use become transformed 
over a period of time (Latour, 2005). In Science and Technology Studies literature, the notion 
of configuration has been previously employed to explore the mutual constitution of social 
and technological change and transition (Geels, 2002; Rip and Kemp, 1998). In the context of 
technology development and use, Fleck (1993; 1994) provided an analysis of technological 
systems as technological and non-technological components (re-)configured to meet local 
contingencies. 
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This study mobilises the concept of reconfiguration to explore the ways in which 
technological innovation becomes incorporated into everyday practice. We seek to combine 
the concept of reconfiguration with ideas from ‘practice-based’ studies that have gained 
currency amongst organizational and healthcare researchers (Gherardi, 2010). Drawing upon 
Schatzki’s (2001) notion of ‘field of practices’, we argue that viewing adoption as a process 
involving spatially and temporally distributed reconfigurations across technologies, 
professionals, patients, organizations and healthcare systems provides for a more holistic 
analysis. 
The empirical backdrop to this discussion is provided by a case study exploring the adoption 
of Breast Lymph Node Assay (BLNA), a diagnostic innovation for the treatment of breast 
cancer patients. Our study reveals that BLNA adoption requires reconfigurations across 
multi-level fields of practice that are not always easy to implement or even identify a priori. 
In particular, we show how reconfigurations of clinical and related work practices, and of 
inter-organisational relations can become a major stumbling block. In so doing, we further 
explore the ways in which emergent practices shape the adoption of BLNA and are shaped by 
it. 
This paper is organised as follows. The next section summarises the literature on the adoption 
of technological innovations in healthcare and, in particular, the ‘technology in practice’ 
perspective and Schatzki’s (2001) notion of ‘field of practices’. Subsequent sections describe 
the methodology and the context of the case study. The case study is then presented and the 
main findings are discussed. The paper concludes with a discussion of the contribution to the 
field of technological innovation in healthcare. 
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Reconfiguring Technology Adoption in Practice 
Social science studies have contributed towards the wider analysis of innovation processes, 
however, often implicitly and/or explicitly they assume a clear demarcation between 
functional forms of analysis, where the ‘structural properties’ of innovation are considered as 
key elements of success, and more critical or sociological approaches that emphasize the 
political nature and the social ramifications of innovation (Greenhalgh et al., 2004; 2005). 
Drawing upon distinctive theoretical and methodological foundations, each approach offers a 
different analytical lens and often contrasting explanations about the nature, role and 
influence of technological innovation (Timmermans and Berg, 2003). In so doing, they 
reduce explanation to particular disciplinary conditions (i.e. either structural properties or 
human agency is given analytical primacy). 
More recent research on the co-adaptation of work practices and new technologies has 
identified alternative conceptual ways of analyzing the nexus (and effects) of agents, objects 
and their context in situated practice (Gherardi, 2010; Leonardi, 2009; Timmermans and 
Berg, 2003). Drawing upon in-depth qualitative and ethnographic studies, ‘practice-based’ 
studies have focused on the way people actually make sense of, and work with, technology 
(e.g. Hartswood et al., 2002; 2003; Jirotka et al., 2005; Luff et al., 2000; Maniatopoulos et al., 
2009; McLoughlin et al., 2009; 2012). In the context of technological innovation, practice-
based orientations emphasize the inherently situated and/or enacted nature of adoption (i.e. 
technology is implemented in a specific, local context) (Berg, 1997; Gherardi, 2006; 2010; 
Greenhalgh and Swinglehurst, 2011; Lehoux et al., 1999; Lehoux et al., 2004; Nicolini, 2006; 
Pasveer 1989). Nicolini (2006: 2755) suggests, for example, that analyzing technology in 
practice means “shifting the attention from the supposed effects of technology to the 
relationships and actions that attach meaning to the new technology and that stabilize its use 
within the extant work and organizational practices.” Such a perspective provides a way of 
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analyzing technological innovation where technology itself is considered as a more emergent 
and contingent socio-technical entity (Timmermans and Berg, 2003). This reflects what has 
been identified as the ‘ensemble view’ of technological innovation, highlighting not only the 
technological artefacts, but also the social and organizational aspects surrounding those 
artefacts, i.e. the interaction between technologies and social structures around them (May, 
2013).  
A distinguishing feature of practice-based approaches is their emphasis on the appropriation 
of technology by user organizations through local reconfigurations. This involves both 
“practical efforts to make technology work” in a specific context and action to “create 
meanings” that enable a technology to become embedded in the identity and culture of user 
communities (Williams et al., 2005: 55; 58). As such, new technology will be still further 
shaped during adoption and use in what has been called ‘innofusion’ (Fleck, 1988). Practice-
based approaches highlight the highly contingent and malleable nature of technology use by 
identifying both intentional and unintentional changes resulting from local reconfiguration 
and situated innovation. In these processes, the boundary between technology, organization 
and use, far from being given and/or fixed, becomes both socially configured and 
reconfigurable, thus allowing alternative ways of constructing technologies’ potential 
meanings and uses.  
Moving Beyond the Situated Enactment of Technology in Local Practice 
Although practice-based orientations have undoubtedly shifted the focus from the effects of 
technology to its appropriation, it is suggested that most studies have been primarily 
concerned with the specifics of situated micro-level activities and local performances (Brand, 
2010; Geels, 2010; Orlikowski, 2010; Schatzki, 2011; Shove et. al 2012; Watson, 2012). This 
focus is particularly problematic when one considers the large-scale and complex nature of 
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national healthcare technology innovation and implementation programmes. While exploring 
the situated meaning of human action and experience is fundamental to any understanding of 
practice, it is argued that this micro-level focus of practice “while foundational, risks missing 
the radical implications and potential of the concept.” (Watson, 2012: 489) In particular, it is 
suggested that this fascination with the detailed understanding of local practice can produce 
empirical and theoretical “micro-isolationism”, whereby “a local empirical instance is 
interpreted wholly in terms of what is evidently present, cut off from the larger phenomena 
that make it possible.” (Seidl and Whittington, 2014: 1408)  In so doing, there is a tendency 
to treat organizations and thus technologies as “the isolated containers of focal phenomena” 
(ibid). 
In recent years, a renewed interest in the study of practice has introduced a new ‘practice 
theoretical approach’, which aims to provide a framework for a more integrative analysis of 
social, cultural and material aspects of ‘social practices’ (cf. Reckwitz, 2002; Schatzki, 2001). 
As one of the key drivers of this movement, Schatzki (2001) has sought to explore ways in 
which social practice may be better explained by reference to different ‘fields of practices’. 
Drawing upon a diverse strand of social theories (Bourdieu, Foucault, Giddens), Schatzki 
(2001) describes practice as a ‘distinct social ontology’, which sets it apart from both 
functional forms of analysis and more sociological approaches. He argues that from a practice 
orientation “the social is a field of embodied, materially interwoven practices, centrally 
organized around shared, practical understandings. This conception contrasts with accounts 
that privilege individuals, (inter)actions, language, signifying systems, the life world, 
institutions/roles, structures, or systems in defining the social. These phenomena, say practice 
theorists, can only be analyzed via the field of practices.” (Schatzki 2001: 3)  From this 
perspective, ‘fields of practices’ can be understood as the total nexus of 
interconnected/interdependent human practices (practice-arrangement bundles) that unfold 
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across multiple contexts in space and time. As Schatzki (2011:13) puts it “the site of the 
social is a mass of linked practices and arrangements spread out across the globe and 
changing through time. All social phenomena are slices or aspects of this mass.” This 
definition of practice implies that an organization consists in interrelated practices distributed 
across interconnected social, cultural and material orders. In this view, a hospital department, 
for instance, consists in interrelated practices of caring, diagnosing, treating, commissioning, 
advising, decision making, etc. that cut across departments, services, wards, offices, operating 
rooms, laboratories, and so on.   
Drawing upon these ideas, we propose to move beyond the situated enactment of technology 
in local practice towards the wider landscape of interconnected practices distributed in space 
and time. In so doing, we seek to develop closer connections between the micro-level 
reconfigurations and the wider socio-political arrangements shaping the adoption and the 
embedding of technological innovation in healthcare. For the purposes of this study, adoption 
is considered as a process of spatially and temporally distributed reconfigurations across 
technologies, professionals, patients, organizations and health systems. Such reconfigurations 
are distributed across a multi-level set of practices, ranging from the macro-political economy 
context to inter-organizational arrangements between healthcare organizations and the micro–
level setting of individual action. It is important to note here that this does not imply an 
‘order’ of the social practice, with a pre-existing ‘top’ and ‘bottom’ hierarchy/dichotomies of 
cause and effect. Rather, we argue that ‘levels’ are just “different components or sectors of a 
single plenum embracing spaces of innovation and spaces that perpetuate the past and 
present.” Schatzki (2014: 16) From this perspective, local practices are both the medium and 
outcome of larger reconfigurations (and vice versa) they recursively organize across multiple 
contexts in space and time. It is the actual process of reconfiguration across interconnected 
‘fields of practices’ that enables innovations to become embedded in everyday practice. 
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Research Setting and Methods 
This article draws upon a three year UK research study, which explored the organizational 
and policy context for successful technology adoption in a national technology innovation 
and implementation programme in the National Health Service (NHS) in England. We 
examined the adoption of three healthcare technologies: insulin pump therapy; a breast lymph 
node metastases diagnostic (BLNA); and an ultra-wide field diagnostic for retinal imaging 
(Llewellyn et al., 2014). This paper reports on the adoption of BLNA.  
The NHS National Technology Adoption Centre (NTAC) was set up with the aim of 
increasing the adoption of technological innovations that had been identified as having the 
potential to deliver significant benefits to the healthcare system and its patients (NTAC was 
subsequently absorbed within the National Institute for Health and Care Excellence (NICE) 
(www.nice.org.uk) as the Health Technologies Adoption Programme. See www.ntac.nhs.uk). 
It functioned as an advisory body on policy to the UK government and as a ‘change agent’, 
promoting the uptake of technologies through its Technology Implementation Projects. In 
2008, NTAC announced a call for proposals for its Technology Implementation Projects and 
BLNA was one of the innovations selected. The evidence base for BLNA was considered 
strong and adoption was consistent with the National Institute for Health and Clinical 
Excellence’s guidance for breast cancer care (NTAC, 2011):  
The intra-operative analysis of sentinel lymph nodes offers the opportunity to 
streamline the management of breast cancer patients as part of a cohesive and 
comprehensive service, and according to a review in the Histopathology Journal (July 
2009), this test is accepted as a reliable technique. 
Hospital Trusts (a Trust is a division within the NHS providing healthcare services (e.g. acute 
care) within a geographical area) across England applied to take part in the implementation 
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project in the spring of 2008 and four sites were selected. These consisted of a ‘mentor site’ 
(a Trust that had already adopted the technology and which would provide support for the 
other sites, ‘MS’ in Table 1 and following text) and three ‘implementation sites’ (IS 1, 2 or 3) 
(Trusts that wanted to introduce BLNA).  
Following NHS (Regional Research Ethics Committee), and local R&D approvals, 
participants were approached to take part in the study. Purposive sampling was employed to 
ensure inclusion of all relevant individuals. Participants included clinicians, chief executives, 
procurement/commissioner managers, project managers, and other specialists. Two 
researchers (GM and RP) conducted the fieldwork.  
Data collection was based on semi-structured interviews (34 in total; see Table 1) between 
March 2010 and September 2011 with key informants at each site, supplemented by 
participant observation of project meetings, and review of Trusts’ internal documents and 
policies related to technology adoption. Participants were provided with information sheets in 
advance, and consent forms signed prior to the start of the interviews. All interviews lasted 
between 60-90 minutes, and were digitally recorded and transcribed.  
Interviews were supplemented by observations of 4 meetings, organised by NTAC, where 
representatives of each participating Trust gathered to be updated on the current status of the 
project and to discuss issues related to its execution. These meetings were conducted away 
from participants’ sites and involved a wide range of stakeholders (clinicians, 
histopathologists, nurses, procurement officers and other Trust managers). For reasons we 
describe in more detail below, these meetings were often tense and involved a high level of 
uncertainty among the various participants about the required changes in clinical protocols.  
Transcribed interview data and fieldwork notes were analysed using thematic analysis to 
generate category systems and repeated themes (Boyatzis, 1998). Drawing upon an 
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interpretative approach, themes were developed in an iterative and inductive way, breaking 
down and reassembling the data through a coding process. For the purposes of inter-coder 
reliability, two (GM and RP) researchers analysed the data independently. These were later 
discussed and approved by the research team. For confidentiality reasons, all participants 
have been anonymised.  
It is important to note that the timeframe of the study meant that we were only able to observe 
a specific period within an ongoing and potentially drawn out adoption process. 
TABLE 1 ABOUT HERE 
Breast Lymph Node Assay 
Breast cancer affects more than 45,000 women each year in the UK (Cancer Research UK, 
2013). Under the established breast cancer clinical pathway, a patient diagnosed with breast 
cancer will undergo a mastectomy, during which the so-called ‘sentinel lymph’ node is 
removed and tissue sent for analysis (Cserni, 2012; Layfield et al., 2011; Somasundaram et 
al., 2011). If this biopsy shows that there has been a metastasis (i.e. the cancer has spread to 
the sentinel lymph node), the patient is then readmitted for a second operation to remove the 
remaining (axillary) lymph nodes. Apart from the additional psychological stress from having 
to endure a second hospital admission and operation, the current pathway can pose a clinical 
risk for patients as the cancer has further time to metastasise. 
BLNA is a new diagnostic technology, the results of which can be ready within 30-45 
minutes and so can be completed intra-operatively. If metastases in the lymph nodes are 
identified, surgery is extended to allow the remaining lymph nodes to be removed. Hence, 
BLNA represents an improvement on patient care, as measured by fewer bed days and a 
shorter care pathway, and patient outcomes, as measured by increased survival rates (Layfield 
et al., 2011; NICE, 2009). 
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Findings 
In the following sections, we explore BLNA adoption issues as they touched on a number of 
interrelated “fields of practices”, ranging from the patient pathway, the non-surgical practice 
of histopathologists in the pathology lab, clinical practice in theatre, as well as the inter-
organisational arrangements between healthcare providers (i.e. the Trusts) and 
commissioners, and, finally, the wider political economy of healthcare policy.  
Reconfiguring the patient care pathway 
Patient benefits 
Our evidence points clearly to BLNA being an innovation championed by clinicians. All the 
surgeons in the participating Trusts stressed that their support for BLNA was on account of 
the important benefits it would have for patients: 
Surgeon 2, IS3: Well to be honest it was a no brainer, you’ve got reduced length of 
stay, reduced hospital visits, reduced anaesthetics, theatres, reduced surgeon’s time 
… it was a no-brainer that if you could do this as a one-hit operation then that’s what 
patients would want.  
Trust managers also saw a clear clinical case for adoption and savings for the health 
economy:  
Director of strategy and planning, IS2: Because clearly that’s good for patients 
because it reduces the number of operations. It’s good for clinicians because they get 
a result quickly, and it’s good for the people who are paying our bills because they 
see a saving.  
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Reconfiguring patient management 
While a shorter care pathway and fewer hospital inpatient episodes would be welcome to 
patients, there were side effects that might put patient acceptability in question. These stem 
from the fact that the exact course of the procedure would depend on the outcome of the 
BLNA. Dealing with them would require some reconfiguration of patient management, but 
how much was not initially clear. Most straightforwardly, there would have to be a change to 
the consenting process so that surgeons could proceed with the removal of the auxiliary nodes 
if the BLNA was positive: 
Surgeon 2, IS3: The patient’s consent has to be careful because the patient is 
consenting for a sort of either/or option and therefore consent can be arguably a little 
bit difficult, because you’re saying to a patient, we’re going to do this, if it’s positive, 
we’ll do your axilla and if it’s not, we won’t and therefore there’s an uncertainty. The 
patient’s going to wake up with an uncertainty. The first thing they’re gonna say to 
you is, was my axilla clear?  
Surgeons did not anticipate the need for major changes to the consenting process. In contrast, 
breast care nurses emphasised the need to consider the psychological impact for patients of 
the ‘one-step’ rapid diagnostic test and instant clinical intervention: 
Breast care nurse, IS3: Yes as you say, it is really for them, the uncertainty of, you 
know, will the test come back showing that I don’t need to have any lymph glands 
removed, therefore, you know, my cancer is not as bad as it could be. Or if they come 
back positive then, oh dear my cancer is, you know, as bad as it can be … And it’s the 
psychological impact of that.  
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Their view that insufficient attention had been paid to how they would manage patients’ 
responses to this uncertainty, suggested a divergence in understanding of the challenges of 
managing the patient among surgeons and nurses: 
Consultant Nurse, MS: I think what we haven’t thought through with this technique 
is how we support patients … The patient will go to sleep with uncertainty about what 
they will wake up to. … So that nobody really had a lot of consultation with her about 
that dread that she felt when she woke up’.  
Breast care nurses argued for the provision of post-operative support for patients, as one 
surgeon acknowledged, while pointing out that this would have cost implications: 
Consultant breast surgeon, IS1: The breast care nurses would like to be there for 
the patient when they’re waking up so that, you know, they’re waking up and they 
know the prognosis is not so good, but they’ve got someone who they know and who 
has some expertise. And so that’s time and money for the breast care nurses as well.  
In summary, surgeons and nurse were in agreement about the benefits of BLNA for patients. 
Both groups also recognised that changes to patient management would be necessary, but 
they differed in their views about what changes should be implemented. Reconfiguration of 
patient management would be the least complex of adaptations that would be required for 
BLNA adoption. 
Reconfiguring non-surgical workflow and practices 
Adoption of BLNA would only be possible with reconfigurations in clinical workflow and 
practices across various departments: surgery, pathology, outpatients, follow-up clinics, etc. 
Indeed, while the adoption of BLNA was expected to demand reconfigurations of non-
surgical and clinical practice, their exact form and how significant they would turn out to be 
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depended on local factors at each site, necessitating, in some cases, a lengthy series of 
negotiations within and between the different staff groups involved. 
Histopathologists’ workload 
Pathology staff would now have to be available to test tissue samples on demand, a change 
that increased the pressure on them. The test had to be completed within a short time frame, 
which meant that a histopathologist had to be available: 
Histopathologist, IS2: …the big thing for us is we knew it was going to be a high 
pressure test with a lot of pressure on a biomedical scientist to provide that result 
accurately and quickly with a surgeon banging on your door.  
Hence, there was a general concern that the short time available to conduct the test would 
make histopathologists’ job more difficult.  
Spatial reconfiguration 
The need to complete the test quickly also meant that the sample had to get to pathology with 
minimum delay. Where pathology was in the same building as theatre, this was not a 
problem. In other cases, the solution was having “runners” available to collect samples from 
theatre as soon as they are ready, or adapting a room close by for pathology use. The latter 
had significant cost implications: 
Clinical lead, IS2: There’s a room identified … that can be used yes so that’s why we 
are going to build, well they have to remove this and make it into a proper lab and 
that is going to cost about £14,000.  
A consequence of physically relocating the assigned histopathologist close to theatre was that 
they would be deprived of support of colleagues when faced by a difficult diagnosis, thereby 
increasing the risk of error: 
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Histopathologist, IS2: … there will be a single biomedical scientist isolated away 
from their colleagues in a room with a surgeon wanting a result.  Here [in the lab], if 
you’re struggling with a frozen section because it’s difficult to cut you can call on a 
colleague, There, you won’t be able to do that, you will be isolated and that’s, to me 
is the real difference…  
There were also concerns that the combined effects of these individual changes to pathology 
lab work might result in the need to recruit additional staff, further escalating costs: 
 Biomedical scientist, IS2: We are without a doubt having to struggle badly for staff 
when this gets implemented, 3 days a week with a qualified member of staff out to 
satellite lab [in theatre] all day, it’s going to hit us hard.  
In summary, pathology staff faced several challenges from BLNA adoption, ranging from the 
impact of time pressures and, in some cases, isolation from other laboratory members on the 
reliability of results, to dealing with the additional workload.  
Reconfiguring surgical workflow and practices 
Management of theatre lists 
Extra time would be needed in theatre when the BLNA was positive, making management of 
theatre lists more complicated. However, while this was anticipated by surgeons and theatre 
staff, how these changes should be best managed was a matter of continuing debate during 
project meetings and involved managing a high level of uncertainty among the various 
participants about the required changes in clinical protocols. From a clinical perspective, 
changes to theatre list management were, to some extent, a matter of trial and error: 
General Manager of Surgery, MS: So there are going to be some patients that will 
need the clearance, and others won’t, so what are we going to do about that? … 
Theatre planning, in terms of advance planning we don’t know how much of that 
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theatre capacity will be needed … we’re trying to get a better throughput in theatres, 
this conflicts with that slightly, in terms of having to allow the flexibility to, to have an 
extra 15 or 20 minutes on the session for each of these procedures, not all of which 
would be used ... the figures I’ve got is 28 to 30 percent would need the further 
surgery.  
Given these concerns, getting theatre staff on board was perceived to be a major concern for 
BLNA adoption: 
Biomedical scientist, histology, MS: It became very difficult to get theatres to agree 
to go live, to actually start acting on our results ... because if the result is positive, 
then further surgery will ensue, this could go on for another half hour to an hour, if 
you have three cases on the list … if they’re all positive then that list is going to 
overrun … That was my biggest barrier, was getting the theatre staff on board.   
Various changes to theatre management were being experimented with as a way of mitigating 
the knock-on effects of additional surgery: 
Surgeon 2, IS3: It’s 40 minutes for the surgeon to twiddle their thumbs and surgeons 
don’t like twiddling thumbs. So we work around that you go in, you do your sentinel 
node, you send it off and then you tackle whatever breast pathology you’re dealing 
with.  
One approach was to assume test results would be negative and to ‘close up’ patients while 
waiting for the result: 
Surgeon 2, IS3: The phone call comes, negative, wake the patient up. The drip is 
already on, the stitches … the wound’s already closed ... If the phone call says it’s 
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positive, then basically just get gowned and gloved, the registrar’s there, takes the 
dressings all down, cuts the skin and stitches back, we’re straight back in. 
However, such ‘in surgery’ workarounds have their limitations: 
Consultant histopathologist, MS: You get the list and there may be two sentinel 
lymph nodes on there first and second cases and you think: Excellent. But something 
happens and for some reason, either the patient’s cancelled or they get pushed down 
the list and then you’ve got the person waiting over there to do the assay not doing 
anything else … then it’s basically wasted time.  
Consultant Breast Surgeon, MS: [If] it finishes late then you’ve over utilised your 
list and conversely if you’ve got three patients on and you’re expecting one of them to 
be positive and none of them are positive you may underutilise your list. 
Hence, a question that preoccupied surgical teams at each Trust was how best to organise the 
theatre list to accommodate the possibility of a patient requiring a second procedure while 
limiting the disruption to the list as a whole. One approach was based on trying to predict 
which patients would be more likely to test positive: 
Clinical lead, IS2: If somebody has a high risk tumour, a grade three tumour which 
is large it is more likely that they are likely to be positive than somebody with a 
smaller tumour which is grade one or grade two. So you will want to leave the grade 
three ones towards the end of your list rather than, because if you do the grade three 
ones in the beginning and then it’s positive then you’re going to spend more time  
Surgical and non-surgical workflow coordination 
Theatre list management issues emphasised how BLNA adoption depended on a closer 
coordination between theatre and pathology teams: 
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Clinical lead, IS2: And also you want to do it within time because the pathologist 
maybe has to leave at five o’clock so you don’t want to leave your last sentinel lymph 
node later that four o’clock. So you want to do that within time and this procedure 
has such a crucial working relationship with the pathology department actually.  
However, despite theatre staffs’ efforts, there could be no guarantee that things would go 
according to plan. In extreme cases, operations might have to be cancelled, but this risked 
disruption to wider theatre list planning, quite apart from the stress and anxiety inflicted on 
the patient. Overall, reconfiguring non-surgical/clinical workflow increased pressure on 
histopathologists and the possibility of disrupted theatre lists, with negative consequences for 
patients, theatre staff, workflow and costs.   
Reconfiguring inter-organizational relations and practices 
Making the business case 
Any decision to adopt BLNA would be subject to Trusts gathering evidence and making a 
business case: weighing up cost savings and additional costs incurred. For Trust managers, 
having to negotiate with different staff groups made making the business case for BLNA that 
much more difficult: 
Operational manager for breast, IS1: The complication with this is that you're 
working with the labs and you're trying to pull the business case together for lots of 
different factors, whereas generally, as a business case, you'd write it for yourself and 
your own department.  You’re trying to sort of pull it together from all different areas.   
Once compiled, the business case would be prioritised against competing business cases: 
Operational Manager for Breast Care, IS1: We started to work up the business 
case for the inter-operative analysis alongside other business cases for breast care ... 
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The one that didn’t go forward was the intra-operative assessment analysis, and 
that’s the one that we’re putting forward this year … Because there’s only a finite 
amount of money … and that scheme was not given priority … It would be quite 
surprising to get support for more than one big business case actually in one 
directorate.  
One reason why BLNA might not be prioritised would be the lack of a national tariff. 
Payment by Results (PbR) is the system in NHS England under which commissioners pay 
healthcare providers for each patient treated, taking into account the complexity of the 
patient’s healthcare needs (Department of Health, 2012a). Innovations such as BLNA may 
not be covered by national tariffs because, initially, they are offered by few Trusts 
(Department of Health, 2012b). In such cases, a local tariff, or ‘pass-through payment’, must 
be negotiated between provider and commissioner. In this context, adopting BLNA presented 
Trusts with a major problem. Put simply, commissioners (at the time of study, commissioners 
were Primary Care Trusts (PCTs). These have since been replaced by Clinical Care 
Commissioning Groups) stood to gain from reduction in bed days and theatre time because 
two operations were being replaced by one, while the providers, the Trusts, stood to lose 
income for the same reasons: 
Pathologist, MS: What we did have to do was put a business case together and 
convince the Trust’s Planning Committee that that was a good idea. Clinically and 
financially. In fact I think they got their sums wrong and we probably shouldn’t have 
been doing it! What I hadn’t realised was that saving the NHS money did not 
necessarily save the Trust money. It saves the PCTs money but the PCTs don’t pay 
that money to the Trust so the Trust actually loses money. It is much better for the 
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Trust to do two operations rather than one because they get two tariffs. Which is one 
of the crazinesses.  
Consultant breast surgeon, IS1: The Trust actually loses money in that they don’t 
get the income from the second operation anymore … it does mean that from a 
financial point of view and a service provision point of view … there may be some 
reticence from a hospital to lose income, even if it’s also less work.   
One strategy was to look for savings elsewhere: 
Operational manager for breast, IS1: As a pragmatic business manager, you have 
to say that if this is going to cost you [the Trust] more [because] you’re losing 
income, [and] the assay alone is £250 a time, plus all the lab costs. So the only way 
we could take that hit is either to get more money from the commissioners or to make 
savings within our own department to offset the cost. And that’s the difficulty we 
have; how can we identify savings to support this?  
Some saw the root of this problem as the ‘silo’ culture, where departments operate as 
independent units, and argued that the healthcare economy would benefit from a more 
integrated approach: 
Lead pathologist for breast pathology, MS: Throughout the Health Service there’s 
no global view. Every section has to worry about its budget so that if one section 
saves money for somebody else they may be penalised but the other section benefits, 
whereas what actually matters is that the patients are getting a better service and 
potentially is saving money as well.  
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Negotiating a tariff 
The financial barrier to BLNA adoption could only be resolved through negotiation between 
the Trusts and their PCTs of a pass-through payment that was acceptable to both parties. 
Much would then depend on the relationship between the Trust and its PCT: 
Operational manager for breast, IS1: I would say we have a good relationship with 
our commissioners, but we all recognise that we’re not in a time of plenty … The best 
outcome would be if the commissioners said, “Yeah, we recognise it’s best for 
patients. We accept it’s a cost pressure to you. We will give you a local tariff,” which 
is over and above what we get for PbR, then we'd be fine … But it’s not going to be 
that easy because the commissioners have an efficiency target to meet as well and, 
you know, they’ve got lots of other services that are coming to them in the same way 
with innovation.  
Reflecting on previous experiences, IS2 staff felt that local negotiations between Trusts and 
PCTs could be a lengthy process:  
Directorate manager of pathology, IS2: Having been through the process on 
several occasions you know with business cases, it always seems to come down to 
those local negotiations that are going to go on between the PCT and the Trust and 
that in reality is what’s taken the time to get sorted out.  
In summary, without some flexibility in the contractual relations between Trusts and the 
PCTs to enable negotiation of a mutually acceptable pass-through tariff, resource issues made 
the creation of a credible business case for BLNA difficult if not impossible.  
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Reconfiguring commissioning policy and practice 
In the view of Trust business managers, the reluctance of PCTs to share the financial 
implications of adoption had a powerful, negative impact on their capacity to innovate and 
led them to question the lack of push for innovation at a national level: 
Operational Manager for Breast care, IS1: So why isn’t there a dialogue at a 
national level between the PbR national guidance around tariff and innovation? So if 
you could have done that in the very early stages to say this is a new innovation, you 
know, we recognise it costs more than the current one but the patient experience is so 
much better, if it would actually come with a new tariff, then, actually, you’d be 
halfway there …  
One consequence was that there was the lack of a clear process for Trusts to follow when 
negotiating a pass-through payment: 
Assistant Director of Commissioning, IS3: And we came together with well what on 
earth, there must be a mechanism under the tariff in some way of introducing an 
incentive to put this in place … a pass-through payment ... What happened was our 
finance person contacted the strategic health authority  [Strategic health authorities 
were responsible for implementation of national healthcare policy in England at 
regional level. They were abolished in 2013]  who contacted the Department of 
Health to find out how we could work this, because I think initially for us in the first 
year it was going to be more expensive ... So we had to justify that..  
At a policy level, NTAC attempted to persuade the National Institute for Health and Care 
Excellence (NICE) that, if the latter made a technology mandatory it, should also create an 
interim tariff for it, but this came to nought: 
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NTAC, CEO: NICE puts out a guideline for a new piece of technology, which may 
not have a tariff. It tells the Trust they have to adopt it but it doesn’t tell them how 
they’re going to get paid for doing that. What I was trying to push NICE to do is 
create an interim [tariff] for the moment that the guidance is given so that a Trust can 
start using it and develop some reference costings around it. But that’s going to take 
time coming through and NICE, of course, is going to have to change. 
In summary, without a reconfiguration of commissioning policy and practice, any innovation 
whose adoption might result in financial penalties for healthcare providers (or, indeed, 
commissioners) might struggle to get adopted. Perhaps in recognition of this problem, a 
subsequent report on ‘Innovation, Wealth and Health’ (Department of Health, 2011) stated 
that healthcare commissioners should “adopt best practice” as part of their legal duty to 
innovate. 
Discussion  
Drawing upon Schatzki’s (2001) notion of ‘field of practices’, this paper has explored how 
technology adoption depends on reconfigurations distributed across a multi-level set of 
practices. We explored these issues through a case study of the adoption of BLNA, which 
illustrated how it is difficult – if not impossible – to propose a ‘standard’ pathway for its 
embedding into healthcare practice. Although the adoption of BLNA promised benefits over 
existing practice(s) such as the opportunity to streamline the management of breast cancer 
patients, we saw how its adoption also involved reconfigurations across a multi-level set of 
work practices that were not always easy to implement.  
When the Trusts in this study began to prepare the ground for BLNA adoption, the prospects 
must have seemed good, the basic case was strong and, when looked at from the perspective 
of the NHS as a whole, unambiguous in terms of patient benefits and cost reduction, and 
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consistency with NICE guidelines for breast care. Surgeons were unanimous about the patient 
benefit and their role as organizational champions clearly made a difference (Hendy and 
Barlow, 2012). Our data however, suggests that whilst organizational champions can be 
important facilitators of technology adoption, reconfigurations of work practices within and 
across departments and professional groups (Ferlie et al., 2005) to support the adoption of 
BLNA requires much more. In particular, BLNA adoption called for a number of significant 
reconfigurations in working practices of non-surgical and clinical teams, some of which 
could be anticipated in advance, while the nature of others would only become clear over 
time. It necessitated the need to train pathology lab staff in the skills required to perform the 
assay, a task that was relatively easily satisfied. Trusts found it less easy, however, to meet a 
core requirement – rapid testing and reporting back of results, which demanded closer 
coordination between surgical teams and pathologists. We saw different ways of achieving 
this at each Trust, some of which were acknowledged to introduce some potential risk to the 
reliability of testing procedures. Ideally, the assay would be done in theatre, in an adjoining 
room or, at least, in the same building. However, not all of the Trusts could satisfy this 
requirement without making significant changes: e.g. relocating pathology; creating a new 
‘satellite’ pathology lab next door to theatre; using ‘runners’ to take the biopsy to the 
pathology lab and return with the results, which added to costs.  In line with our findings, 
previous studies have pointed out the ways in which new technologies, such as BLNA, have 
the potential to modify the form, structure and range of settings and communication methods 
used within healthcare practice (Poland et al., 2005; Andrews and Evans, 2008). 
The need for such reconfigurations offers an important insight for understanding how 
emergent practices are shaped by – and shape – innovation. BLNA demanded some 
reorganisation of pathology lab work, as surgical and pathology teams have to work more 
closely together. At a minimum this meant that histopathologists would have to be ‘on-call’ 
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whenever a breast cancer surgery list was scheduled, which raised concerns that they would 
be unable to carry out their other duties at these times. For some Trusts, this also meant 
providing a ‘satellite’ testing facility in close proximity to theatre. Such changes raised 
concerns among histopathologists about the impact on the reliability of results of time 
pressures and isolation from other lab members. Regarding the latter, the workplace studies 
research literature on the role of co-location for the routine achievement of dependable work 
in medical and other work settings (e.g. Buscher et al., 2010; Hartswood et al., 2002; 2003; 
Jirotka et al., 2005; Luff et al., 2000) substantiates their concerns about the risks involved. 
At the clinical pathway level, we saw how multiple tensions exist between the requirement 
for reconfigurations to incorporate technology adoption in healthcare practice on the one 
hand and the inherent uncertainty of context and process (i.e. service model) on the other. 
Reconfiguration of theatre lists was necessary as BLNA had the potential to cause both 
under-runs and over-runs of theatre lists. How such reconfigurations would be done would 
vary from Trust to Trust. Overall, it was felt that BLNA made the management of theatre lists 
more complex, as provision had to be made for additional surgical time, but which patients 
would need it could not be predicted with complete confidence in advance. Service level 
adaptation was required not only for breast cancer surgery itself, but also for outpatients, 
follow up clinics, bed use on main wards and other services that shared facilities. 
At an organizational level, the adoption of the BLNA required addressing uncertainty about 
the effectiveness of a proven business model. From a commissioning perspective, making a 
case for BLNA adoption demanded significant inter-organisational work if Trust 
management – and other stakeholders – were to be convinced that this could be done within 
acceptable levels of risk – financially and operationally (Llewellyn and Northcott, 2005). In 
particular, the lack of a national tariff for BLNA necessitated reconfiguration of 
commissioning policy and practices, through the negotiation between Trusts and their PCTs 
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of a ‘pass-through’ payment. As we have seen, these negotiations were contingent on the 
quality of the working relationship between Trust and PCT. Such uncertainties make it 
difficult to incorporate services such as the BLNA in practice and without any local 
negotiations and agreements over funding arrangements they can become a major stumbling 
block. Overall, the lack of a funding model for BLNA meant that value for money assessment 
would be difficult for any Trust considering adopting the technology. 
From a policy perspective, the 2011 UK government report on ‘Innovation, Wealth and 
Health’ (Department of Health, 2011) recognised that patients should have access to the latest 
diagnostics and innovations which is key to improving the health and wealth of the state, as 
well as creating opportunities in private sector for healthcare suppliers. Despite the 
government’s policy objectives, Trust business managers described problems of ambiguous 
or incompatible policy related to national guidance around national tariffs and innovation.  
Moreover, political issues surfaced most clearly in the relationship between providers (the 
Trusts) and commissioners (PCTs) of services, which, for provider business managers, were 
defined by PCT unwillingness to find an equitable solution to sharing costs and benefits. In 
their view, this had a powerful, negative impact on the NHS’s capacity to innovate. As such, 
unless reconfigurations at a policy level were taking place towards the development of a 
funding model for BLNA, its incorporation into routine practice would be very difficult for 
Trusts.  
In sum, this study advances the study of technology adoption in three ways. First, it broadens 
the scope and scale of analysis across the different set of practices that contribute towards the 
successful adoption and incorporation of technology in healthcare. In this study we have not 
simply examined reconfiguration processes within a particular setting of practice, but rather 
have explored reconfigurations distributed across a multi-level set of practices, ranging from 
the policy level to the micro–level setting of individual action. In this way, and by offering a 
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more holistic view of technology adoption, we show how success hinges on how 
organizations, user communities and technologies become reconfigured across interconnected 
social, cultural and material orders. This is of increasing importance, as maximising the 
effectiveness of technology adoption in large-scale national healthcare technology innovation 
and implementation programmes demands greater understanding of the reconfigurations 
processes across the different sets of practices. 
Second, our theoretical positioning stresses the importance of being sensitive to the broader 
context of reconfigurations in which technology adoption is located (Brand, 2010; Geels, 
2010; Watson, 2012). In so doing, our findings reinforce the importance of moving beyond 
the boundaries of local practice towards a broader perspective of interconnected practices 
shaping the adoption and the embedding of technological innovation. Much of the existing 
literature around the adoption of innovation in healthcare has focused on the 
technical/structural properties of adoption or has investigated specific interactions between 
professional groups, rather than exploring adoption as a process over a field of interrelated 
practices (May, 2009; Robert et al., 2010).  
Finally, this study explores the reconfigurations of technology adoption as experienced by the 
practice of a wide range of stakeholders, including clinicians, chief executives, 
procurement/commissioner managers, project managers, and other specialists. As such, it 
provides insights from a variety of different perspectives, thus revealing the multiple 
professional, organisational and social factors that influence and shape the adoption process. 
In so doing, it highlights the issue that however efficacious an innovation may be, its 
adoption in everyday practice can - by no means - be assured.  
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Conclusions  
In conclusion, this paper has used an empirical case study to illustrate how technology 
adoption is a diverse and contingent process, constantly defined, redefined and negotiated. 
The case study enabled exploration of how the social, the material and the spatial properties 
of adoption become reconfigured across a distributed ‘field of practices’. Our particular 
contribution in this paper is to extend the notion of reconfiguration across the multiple levels 
that shape the adoption of technological innovations in healthcare. We acknowledge that a 
potential limitation of our analysis is the focus on a single innovation case study, which raises 
questions about the extent to which this is common to technological innovations in 
healthcare. We would suggest that this presents a useful area for exploration in future studies, 
given the well-recognised problems in translating innovations in healthcare. Through opening 
up this avenue of inquiry, our aim is to contribute to the development of more comprehensive 
analysis of the reconfiguration processes surrounding the adoption of complex healthcare 
innovations into practice. 
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Table 1: List of interviewees 
 
Organisation No. of interviews Interviewees 
Mentor site 
(MS) 5 
Consultant surgeon 
Pathologist x 3 
General surgery manager 
Implementation 
site 1 (IS1) 8 
Consultant surgeon x 2 
Breast care nurse 
Pathologist x 2 
Pathology manager 
Procurement manager 
Operational manager for 
breast care 
Implementation 
site 2 (IS2) 9 
Consultant surgeon x 2 
Breast care nurse 
Biomedical scientist x 2 
Pathology manager 
Breast care nurse 
Procurement manager 
Director of planning 
Implementation 
site 3 (IS3) 10 
Consultant surgeon x 2 
Cancer clinical director 
Pathologist x 2 
Breast care nurse 
Pathology manager 
Procurement manager 
Operational manager 
Data manager 
 
Primary Care 
Trust (for IS3) 1 
Assistant director of 
commissioning 
Community 
research group 1 Volunteer 
Total 34  
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• We explore the ways in which a breast cancer diagnostic technology becomes adopted 
• We identify reconfigurations across a multi-level set of practices 
• Reconfigurations are not always easy to implement or even identify a priori 
• Unsuccessful reconfiguration processes could become a barrier to technology adoption 
